Editas Medicine, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Editas Medicine, Inc. on June 17, 2026. The filing details the outcomes of shareholder votes regarding director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes
No material financial changes are reported in this filing. The document serves to disclose the results of the annual shareholder vote.
Outlook, Risks, and Unusual Items
The filing contains no management commentary on future guidance, risks, contingencies, or unusual items. It strictly reports the voting results from the annual meeting.
Key Facts for Investors
- Director Elections: Stockholders elected Bernadette Connaughton and Elliott Levy, M.D., as Class I directors. Dr. Levy received significantly higher support (37,095,058 votes for) compared to Ms. Connaughton (28,660,181 votes for), with 10,789,549 votes withheld for Ms. Connaughton versus 2,354,672 for Dr. Levy.
- Executive Compensation: The advisory vote on executive compensation passed with 32,914,258 votes for, 6,322,885 votes against, and 212,587 abstentions.
- Auditor Ratification: Stockholders overwhelmingly ratified PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2026, with 64,686,839 votes for and only 774,471 votes against.
- Broker Non-Votes: There were 26,404,190 broker non-votes recorded for the director elections and the executive compensation vote.